Patents Examined by Alana Harris Dent
  • Patent number: 9526759
    Abstract: In certain aspects, the present invention provides compositions and methods for treating or preventing breast cancer in humans.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: December 27, 2016
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • Patent number: 9518990
    Abstract: Disclosed is a method aiding in the assessment of cancer. It involves the use of the secernin-1 protein (SCRN1) as a universal marker of different cancer types. More specifically disclosed is a method for assessing cancer from a liquid sample derived from an individual by measuring SCRN1 in the sample. Measurement of SCRN1 can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: December 13, 2016
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Norbert Wild, Marie-Luise Hagmann, Johann Karl, Julia Riedlinger, Markus Roessler, Michael Tacke
  • Patent number: 9512232
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: December 6, 2016
    Assignees: GANYMED PHARMACEUTICALS AG, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH
    Inventors: Ugur Sahin, Özlem Türeci, Rita Mitnacht-Kraus, Stefan Wöll
  • Patent number: 9475841
    Abstract: The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: October 25, 2016
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'ANGERS
    Inventors: Nathalie Labarriere, Francois Lang, Mathilde Bobinet, Anne Rogel
  • Patent number: 9465030
    Abstract: Provided is a kit for diagnosing at a high reproducibility, said kit being produced by preparing a monoclonal antibody against GPC3 and a monoclonal antibody against SPARC that are superior in quality stability to commercially available and commonly employed antibodies, and using these antibodies.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: October 11, 2016
    Assignees: NATIONAL CANCER CENTER, LSIP, LLC
    Inventors: Tetsuya Nakatsura, Keigo Saito
  • Patent number: 9416169
    Abstract: The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: August 16, 2016
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital
    Inventors: Wayne Marasco, Jianhua Sui, Quan Zhu, Thomas Kupper
  • Patent number: 9409965
    Abstract: This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: August 9, 2016
    Assignee: The Regents of the University of California
    Inventors: Arie Belldegrun, Cho-Lea Tso
  • Patent number: 9409989
    Abstract: The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method further involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and/or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: August 9, 2016
    Assignee: Genetech, Inc.
    Inventors: W. Robert Arathoon, Paul J. Carter, Anne M. Merchant, Leonard G. Presta
  • Patent number: 9404925
    Abstract: An object of the present invention to provide: a human pancreatic cancer antigen and/or a human colon cancer antigen that can be applied to the diagnosis and/or treatment of various types of cancers or tumors including pancreatic cancer and colon cancer as representative examples; a gene encoding the same; an anti-cancer vaccine using the same; or the like. The present invention provides a cancer antigen comprising a protein having the amino acid sequence shown in SEQ ID NO: 1; a peptide comprising a portion of said protein and having immune-stimulating activity; an anti-cancer vaccine comprising said peptide; a DNA having the nucleotide sequence shown in SEQ ID NO: 2, or its complementary sequence or a part or full length of these sequence; an anti-cancer vaccine comprising said DNA; and use thereof.
    Type: Grant
    Filed: June 11, 2008
    Date of Patent: August 2, 2016
    Assignee: MEDINET CO., LTD.
    Inventors: Tetsuya Nakatsura, Yasuharu Nishimura
  • Patent number: 9388247
    Abstract: The present invention provides antibodies that target the first-third domains of N-cadherein and the fourth domain of N-cadherin, for diagnosis and therapy of cancers related to N-cadherein. Methods of diagnosis and treatment utilizing these antibodies are also described.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: July 12, 2016
    Assignee: The Regents of the University of California
    Inventors: Robert E. Reiter, Zev Wainberg
  • Patent number: 9388244
    Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: July 12, 2016
    Assignee: The Regents of the University of California
    Inventors: James D. D. Marks, Marie Alix Poul
  • Patent number: 9382587
    Abstract: The present disclosure relates to a diagnostic marker for breast cancer, having thioredoxin-1 as an active ingredient, and to a diagnostic kit for breast cancer using the same. The thioredoxin-1 is overexpressed in human breast cancer tissue so as to enable the early diagnosis of breast cancer or the early prediction prognosis of breast cancer, and therefore has a valuable use as a diagnostic marker for breast cancer. The present disclosure further relates to a method for the diagnosis of breast cancer comprising measuring serum thioredoxin 1 level. In addition, the method is useful in the early diagnosis of breast cancer thanks to its high diagnostic sensitivity and selectivity.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: July 5, 2016
    Assignee: PAICHAI UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventor: Il Han Kim
  • Patent number: 9381228
    Abstract: Disclosed are methods and compositions that employ FKBP-L polypeptides for modulating angiogenesis and/or tumor metastasis. The FKBP-L polypeptides may be used for the treatment of disorders mediated by angiogenesis such as cancer.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: July 5, 2016
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Tracy Robson, Andrea Valentine, Martin Gerard O'Rourke, David Hirst
  • Patent number: 9345677
    Abstract: The present invention relates to compositions, methods and kits based on the ADAM-mediated cleavage of Her-2. The present invention also relates to treatments for cancer, and in particular, breast cancer, by modulating the ADAM-mediated cleavage of Her-2. Further, the invention relates to compositions, methods and kits based on the surprising synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds in, among other things, inhibiting tumor cell proliferation and inducing cell death. Additionally, the invention relates to novel variants of ADAM15, designated ADAM15 variant 1 and ADAM15 variant 2, now identified and isolated.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: May 24, 2016
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Steven M. Friedman, Peggy A. Scherle, Xiangdong Liu, Krishna Vaddi, Jordan S. Fridman
  • Patent number: 9340601
    Abstract: The present invention relates to a novel form of human EGFR found in certain tumors and conditions. The protein is termed here mLEEK, and the cDNA that encodes it has also been isolated. The mLEEK protein is capable of efficiently inducing the transcription of multiple genes resulting in various physiologic processes. Antibodies directed against the protein can be used for improving the diagnosis of diseases or for the treatment of diseases. The protein itself can be directly used or blocked for therapeutic purposes. Nucleic acid based probes or PCR primers specific for the mLEEK sequence can be used for diagnostic purposes. Inhibitory nucleic acid based molecules, such as antisense, siRNA, or shRNA, may be used for therapeutic purposes. The mLEEK sequence is essentially formed by the skipping of exons 2 through 22 in the EGF receptor gene leading to a fusion of exon 1 to exon 23. Other mutants are disclosed, which include the fusion of exon 1 to exon 24 and the fusion of exons 1 to exon 28.
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: May 17, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Albert J. Wong, Emily Piccione Griffin
  • Patent number: 9314515
    Abstract: Treatments for estrogen receptor and progesterone receptor negative breast cancer or estrogen receptor, progesterone receptor and c-erbB2 negative (triple negative) breast cancer are provided.
    Type: Grant
    Filed: April 22, 2009
    Date of Patent: April 19, 2016
    Assignee: Ludwig Institute for Cancer Research Ltd.
    Inventors: Anita Grigoriadis, Otavia L. Caballero, Andrew John George Simpson
  • Patent number: 9310377
    Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: April 12, 2016
    Assignee: METHERESIS TRANSLATIONAL RESEARCH SA
    Inventors: Paolo Maria Comoglio, Paolo Carminati, Paolo Michieli, Cristina Basilico
  • Patent number: 9296793
    Abstract: The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-?B activity. The modulators may be used, for example, in the treatment of NF-?B-mediated diseases, conditions, and injuries.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: March 29, 2016
    Assignee: The Cleveland Clinic Foundation
    Inventor: Andrei V. Gudkov
  • Patent number: 9273127
    Abstract: The invention provides the sequences of two polypeptides comprising the amino acid sequences as shown in SEQ ID NO:1 and SEQ ID NO:2, which can be used for the preparation of monoclonal antibodies against human p28GANK. The invention also provides the monoclonal antibodies against human p28GANK and their use.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: March 1, 2016
    Assignee: The Second Military Medical University, The People's Liberation Army
    Inventors: Hongyang Wang, Yao Chen, Jing Fu, Dongping Hu, Tao Luo, Liwei Dong
  • Patent number: 9261498
    Abstract: The invention disclosed herein provides methods for the examination and/or quantification of biochemical pathways that are disregukted in pathologies such as cancer and to reagents and kits adapted for performing such methods. For example a correlation between VHL loss and mTOR inhibitor sensitivity in human kidney cancer cells is disclosed, indicating that VHL loss confers autonomous and angiogenic competitive advantages to such cells.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: February 16, 2016
    Assignee: The Regents of the University of California
    Inventors: Charles L. Sawyers, George V. Thomas